On Friday, Arbutus Biopharma Corp (NASDAQ: ABUS) was 0.73% up from the session before settling in for the closing price of $4.12. A 52-week range for ABUS has been $1.69 – $4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 55.33% over the past five years. When this article was written, the company’s average yearly earnings per share was at 12.27%. With a float of $146.67 million, this company’s outstanding shares have now reached $169.87 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees. In terms of profitability, gross margin is 85.7%, operating margin of -821.32%, and the pretax margin is -766.2%.
Arbutus Biopharma Corp (ABUS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arbutus Biopharma Corp stocks. The insider ownership of Arbutus Biopharma Corp is 22.31%, while institutional ownership is 51.24%. The most recent insider transaction that took place on Aug 14 ’24, was worth 32,637. In this transaction Director of this company sold 8,846 shares at a rate of $3.69, taking the stock ownership to the 46,069 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Medical Officer sold 4,358 for $2.31, making the entire transaction worth $10,078. This insider now owns 125,542 shares in total.
Arbutus Biopharma Corp (ABUS) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.12 earnings per share (EPS) during the time that was less than consensus figure (set at -0.11) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.27% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
You can see what Arbutus Biopharma Corp (ABUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.35 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 1.35 million, a positive change from its year-to-date volume of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 71.24%. Additionally, its Average True Range was 0.15.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 68.23%, which indicates a significant decrease from 71.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.20% in the past 14 days, which was lower than the 42.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.98, while its 200-day Moving Average is $3.21. Nevertheless, the first resistance level for the watch stands at $4.19 in the near term. At $4.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.28. If the price goes on to break the first support level at $4.11, it is likely to go to the next support level at $4.06. Assuming the price breaks the second support level, the third support level stands at $4.02.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
There are 188,717K outstanding shares of the company, which has a market capitalization of 783.44 million. As of now, sales total 18,140 K while income totals -72,850 K. Its latest quarter income was 1,730 K while its last quarter net income were -19,800 K.
